Tofacitinib Response in Juvenile Idiopathic Arthritis (JIA) and Collagenous Colitis

Journal of Clinical Rheumatology

Volumn 22, Issue 8, 2016, Pages 446-448

  Tseng, Bryon ^a   Amighi, Arash ^a   Bradford, Kara ^a   Wang, Hanlin L ^a   Getzug, Terri E ^a   Brahn, Ernest ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ATROPINE; BISMUTH; CERTOLIZUMAB PEGOL; DIPHENOXYLATE; INFLIXIMAB; LOPERAMIDE; MESALAZINE; OPIATE; PREDNISONE; TOCILIZUMAB; TOFACITINIB;

ADULT; CARPAL TUNNEL SYNDROME; CASE REPORT; CELIAC DISEASE; CENTRAL SEROUS RETINOPATHY; COLLAGENOUS COLITIS; COLONOSCOPY; CORTICOSTEROID THERAPY; DIARRHEA; DISEASE ASSOCIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FECES INCONTINENCE; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; JUVENILE RHEUMATOID ARTHRITIS; LETTER; LYMPHOCYTIC INFILTRATION; MALABSORPTION; MIDDLE AGED; PRIORITY JOURNAL; QUALITY OF LIFE; SIGMOIDOSCOPY; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 85005993415     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0000000000000456     Document Type: Letter

References (13)

1. Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167: 668-677.
2. Vincenti F, Tedesco Silva H, Busque S, et al. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant. 2012;12:2446-2456.
3. Fernández-Bañares F, Salas A, Esteve M, et al. Collagenous and lymphocytic colitis: evaluation of clinical and histological features, response to treatment, and long-term follow-up. Am J Gastroenterol. 2003;98:340-347.
4. Miehlke S,Madisch A,Voss C, et al. Long-term follow-up of collagenous colitis after induction of clinical remission with budesonide. Aliment Pharmacol Ther. 2005;22:1115-1119.
5. Bohr J, Tysk C, Eriksson S, et al. Collagenous colitis: a retrospective study of clinical presentation and treatment in 163 patients. Gut. 1996;39:846-851.
6. Jessurun J, Yardley JH, Giardiello FM, et al. Chronic colitis with thickening of the subepithelial collagen layer (collagenous colitis): histopathologic findings in 15 patients. Hum Pathol. 1987;18:839-848.
7. Esteve M, Mahadevan U, Sainz E, et al. Efficacy of anti-TNF therapies in refractory severe microscopic colitis. J Crohns Colitis. 2011;5:612-618.
8. Münch A, Ignatova S, Ström M. Adalimumab in budesonide and methotrexate refractory collagenous colitis. Scand J Gastroenterol. 2012;47: 59-63.
9. Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl JMed. 2012; 367:616-624.
10. SandbornWJ, Ghosh S, Panes J, et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014;12:1485-1493.e2.
11. Carpenter HA, Tremaine WJ, Batts KP, et al. Sequential histologic evaluations in collagenous colitis. Correlations with disease behavior and sampling strategy. Dig Dis Sci. 1992;37: 1903-1909.
12. Kumawat AK, Strid H, Tysk C, et al. Microscopic colitis patients demonstrate a mixed Th17/Tc17 and Th1/Tc1 mucosal cytokine profile. Mol Immunol. 2013;55: 355-364.
13. Maeshima K, Yamaoka K, Kubo S, et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-? and interleukin-17 production by human CD4+ T cells. Arthritis Rheum. 2012;64: 1790-1798.